Your gateway to a free society
Article

US Miner Almonty Strikes Major Deal With Africa's Largest Tungsten-Producing Country

US Miner Almonty Strikes Major Deal With Africa's Largest Tungsten-Producing Country Almonty Industries is positioning itself to "become the leading Western producer of tungsten," potentially as early as 2027, as Western buyers confront a severe supply shortage sparked by China and, more broadly, what we've described as "resource nationalism." Bloomberg reports that Almonty has partnered with Rwanda's government, securing a foothold in Africa's largest tungsten-producing nation. The deal aims to accelerate access to existing production and develop a traceable, conflict-free supply chain for Western governments, reducing dependence on China's quasi-monopolistic market...
Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Apr 23, 2026 / Tyler Durden
Trump Orders Navy 'Shoot & Kill' Iranian Boats, Says 'Doesn't Need A Deal' - While Iran Insists Could Build Nuke 'If We Wanted To'
Oct 12, 2026 / Tyler Durden
Europe Learns To Love Tariffs, Canada Learns What Happens When You Don’t
Europe Learns To Love Tariffs, Canada Learns What Happens When You Don’t By Benjamin Picton, senior market strategist at Rabobank US and European equity indices were firmly in the black on Friday as the recent run up in bond yields took a breather. The S&P500 closed 46 points higher at 7811 with strong gains across the real estate, consumer discretionary, healthcare and financial sectors. US 10-year yields were just over 1bp higher on the day, but down by almost 7bps over the course of the week with most of the decline...
Read more
Jun 2, 2026 / Tyler Durden
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.

Support the liberty movement